OP5-005 Using Omnipod 5 in Adults With Type 2 (SECURE-T2D)

In by Hannah Schaffner

OP5-005 Using Omnipod 5 in Adults With Type 2 (SECURE-T2D)

  • Hidden
  • This field is for validation purposes and should be left unchanged.

This is a single arm, multi-center, prospective study that will evaluate the safety and efficacy of the Omnipod 5 Automated Insulin Delivery System in adults with type 2 diabetes requiring insulin therapy.


Inclusion Criteria
  1. Age at time of consent 18-75 years
  2. Diagnosed with type 2 diabetes, on current insulin regimen for at least 3 months prior to screening (i.e. Basal-bolus, basal only or pre-mix)
  3. Basal bolus (long-acting insulin and rapid acting analog) or pre-mix users with A1C <12.0% OR basal users on long or intermediate acting insulin only with A1C > 7.0% and < 12.0%
  4. Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, or Admelog
  5. Participant agrees to provide their own insulin for the duration of the study
  6. Stable doses over the preceding 4 weeks of other glucose-lowering medications as determined by Investigator
  7. Stable doses of weight loss medications over the preceding 4 weeks and throughout the study that may affect glycemic control directly and/or indirectly, except for a dose reduction or discontinuation, as determined by Investigator
  8. Willing to wear the system continuously throughout the study
  9. Deemed appropriate for pump therapy per investigator’s assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities
  10. Investigator has confidence that the participant has the cognitive ability and can successfully operate all study devices and can adhere to the protocol
  11. Able to read and understand English
  12. Willing and able to sign the Informed Consent Form (ICF)
  13. If female of childbearing potential, willing and able to have pregnancy testing
Exclusion Criteria
  1. Use of an AID pump in automated mode within 3 months prior to screening
  2. Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia)
  3. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
  4. Any planned surgery during the study which could be considered major in the opinion of the investigator
  5. History of more than 1 severe hypoglycemic event in the 6 months prior to screening
  6. History of more than 1 episode of diabetic ketoacidosis (DKA) or Hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening; unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis
  7. Blood disorder or dyscrasia within 3 months prior to screening, including use of hydroxyurea, which in the investigator’s opinion could interfere with determination of HbA1c
  8. Plans to receive blood transfusion over the course of the study
  9. Has taken oral or injectable steroids within 8 weeks prior to screening or plans to take oral or injectable steroids during the study
  10. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement
  11. Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal)
  12. Participation in another clinical study using an investigational drug or device other than the Omnipod 5 in the 30 days prior to screening or intends to participate during the study period
  13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the investigator’s clinical judgment
  14. Participant is an employee of Insulet, an Investigator or Investigator’s study team, or immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned
Back to Current Studies